Get the Stockscreener App
1.71
0.58%
-0.01
After Hours:
1.72
0.01
+0.58%
Macrogenics Inc stock is traded at $1.71, with a volume of 479.50K.
It is down -0.58% in the last 24 hours and down -4.47% over the past month.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
See More
Previous Close:
$1.72
Open:
$1.7
24h Volume:
479.50K
Relative Volume:
0.37
Market Cap:
$108.17M
Revenue:
$139.77M
Net Income/Loss:
$-97.62M
P/E Ratio:
-1.0823
EPS:
-1.58
Net Cash Flow:
$-61.71M
1W Performance:
+0.59%
1M Performance:
-4.47%
6M Performance:
+16.33%
1Y Performance:
-28.75%
1-Day Range:
$1.66
$1.73
1-Week Range:
$1.66
$1.83
52-Week Range:
$0.9897
$2.95
Macrogenics Inc Stock (MGNX) Company Profile
Name
Macrogenics Inc
Sector
Industry
Phone
301-251-5172
Address
9704 MEDICAL CENTER DRIVE, Rockville, MD
Compare MGNX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MGNX
Macrogenics Inc
|
1.71 | 108.80M | 139.77M | -97.62M | -61.71M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Macrogenics Inc Stock (MGNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Resumed | Barclays | Overweight |
| Nov-07-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Aug-01-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-31-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-31-24 | Downgrade | Guggenheim | Buy → Neutral |
| May-10-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| May-10-24 | Downgrade | Stifel | Buy → Hold |
| May-10-24 | Downgrade | TD Cowen | Buy → Hold |
| Apr-26-24 | Initiated | B. Riley Securities | Buy |
| Apr-09-24 | Upgrade | TD Cowen | Hold → Buy |
| Mar-04-24 | Reiterated | BTIG Research | Buy |
| Feb-14-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-20-23 | Upgrade | Citigroup | Neutral → Buy |
| Nov-07-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-17-23 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-22-22 | Downgrade | Cowen | Outperform → Market Perform |
| Nov-14-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jul-18-22 | Downgrade | SMBC Nikko | Outperform → Neutral |
| Jul-11-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| May-04-22 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-28-22 | Upgrade | Citigroup | Neutral → Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-04-22 | Initiated | SMBC Nikko | Outperform |
| Nov-17-21 | Resumed | Guggenheim | Buy |
| Oct-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-12-21 | Upgrade | Barclays | Underweight → Overweight |
| Dec-22-20 | Resumed | H.C. Wainwright | Buy |
| Aug-03-20 | Downgrade | Citigroup | Buy → Neutral |
| Jun-01-20 | Upgrade | Guggenheim | Neutral → Buy |
| May-26-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Dec-19-19 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-18-19 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-21-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| May-03-19 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-12-19 | Initiated | Guggenheim | Neutral |
| Feb-07-19 | Upgrade | Citigroup | Sell → Buy |
| Feb-07-19 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-06-19 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Feb-04-19 | Downgrade | Citigroup | Neutral → Sell |
| Dec-10-18 | Downgrade | Raymond James | Outperform → Underperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| May-31-18 | Initiated | Evercore ISI | Outperform |
| Mar-05-18 | Initiated | H.C. Wainwright | Buy |
| Mar-31-17 | Initiated | Raymond James | Outperform |
View All
Macrogenics Inc Stock (MGNX) Latest News
MacroGenics, Inc. (NASDAQ:MGNX) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Big Picture: Is Badger Meter Inc stock suitable for long term investing2025 Bull vs Bear & Weekly Market Pulse Alerts - baoquankhu1.vn
Incyte wins EU backing for MacroGenics-partnered cancer drug in GIT indication - Seeking Alpha
Aug Swings: Whats the fair value of Humacyte Inc Equity Warrant stockJuly 2025 Volume & Daily Chart Pattern Signals - baoquankhu1.vn
Retail Trends: What is the next catalyst for MacroGenics IncQuarterly Profit Report & Advanced Swing Trade Entry Plans - baoquankhu1.vn
MacroGenics (NASDAQ:MGNX) Stock Crosses Below 200-Day Moving Average – Should You Sell? - Defense World
MacroGenics (NASDAQ:MGNX) Stock Crosses Below 200-Day Moving AverageShould You Sell? - MarketBeat
Weekly Trades: Is MacroGenics Inc attractive for institutional investorsWeekly Market Summary & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Will MacroGenics Inc outperform the market in YEAR2025 Biggest Moves & High Conviction Trade Alerts - baoquankhu1.vn
MacroGenics, Inc. (NASDAQ:MGNX) Given Average Rating of "Hold" by Analysts - MarketBeat
[Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Is Via Renewables Inc impacted by rising ratesWeekly Trend Recap & Long-Term Growth Stock Strategies - baoquankhu1.vn
MacroGenics (NASDAQ:MGNX) Stock Price Crosses Above 50 Day Moving Average – What’s Next? - Defense World
Meme Stocks: Is MacroGenics Inc attractive for institutional investorsLayoff News & Smart Money Movement Alerts - baoquankhu1.vn
Will MacroGenics Inc. stock benefit from green energy trendsJuly 2025 Sentiment & Consistent Income Trade Ideas - Улправда
How supply chain issues affect MacroGenics Inc. stockQuarterly Performance Summary & Weekly High Return Opportunities - Улправда
Market Leaders: How supply chain issues affect MacroGenics Inc. stockWeekly Investment Report & Step-by-Step Trade Execution Guides - ulpravda.ru
Will MacroGenics Inc. stock gain from government policiesEarnings Overview Summary & Risk Controlled Swing Alerts - Улправда
How MacroGenics Inc. stock performs in rising dollar environment2026 world cup usa national team quarterfinals young talents pressing system odds analysis breakdown - ulpravda.ru
There's No Escaping MacroGenics, Inc.'s (NASDAQ:MGNX) Muted Revenues Despite A 26% Share Price Rise - simplywall.st
MacroGenics (NASDAQ:MGNX) Cut to “Hold” at Zacks Research - Defense World
MacroGenics (NASDAQ:MGNX) Rating Lowered to "Hold" at Zacks Research - MarketBeat
MacroGenics (NASDAQ:MGNX) Shares Pass Above 50 Day Moving Average – Should You Sell? - Defense World
MacroGenics (NASDAQ:MGNX) Shares Pass Above 50 Day Moving AverageShould You Sell? - MarketBeat
MacroGenics, Inc. (NASDAQ:MGNX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
MacroGenics, Inc. (NASDAQ:MGNX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Is MacroGenics Inc. stock positioned well for digital economyJuly 2025 Final Week & Weekly Breakout Watchlists - Улправда
Will MacroGenics Inc. stock attract more institutional investors2025 Growth vs Value & Technical Confirmation Alerts - DonanımHaber
MacroGenics, Inc.(NasdaqGS: MGNX) dropped from NASDAQ Biotechnology Index - marketscreener.com
Macrogenics Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Is MacroGenics Inc. stock a dividend growth opportunityJuly 2025 Action & Weekly Market Pulse Alerts - Улправда
MacroGenics Insider Ups Holding By 909% During Year - simplywall.st
Analyzing MacroGenics Stock: To Buy Or Wait? - StocksToTrade
EcoR1 Capital LLC Purchases New Shares in MacroGenics, Inc. $MGNX - MarketBeat
Will MacroGenics Inc stock attract more institutional investorsRecession Risk & Real-Time Volume Triggers - moha.gov.vn
MacroGenics (NASDAQ:MGNX) Stock Passes Below 200 Day Moving AverageHere's What Happened - MarketBeat
Reviewing MacroGenics (NASDAQ:MGNX) & Exagen (NASDAQ:XGN) - Defense World
Wall Street analysts’ outlook for Macrogenics Inc (MGNX) - setenews.com
What analysts say about MacroGenics Inc stockReal-Time Stock Alerts & Free Tremendous Portfolio Expansion - earlytimes.in
MacroGenics (NASDAQ:MGNX) Shares Cross Below 200-Day Moving AverageHere's What Happened - MarketBeat
MacroGenics (NASDAQ:MGNX) Shares Cross Below 200-Day Moving Average – Here’s What Happened - Defense World
IM Cannabis (NASDAQ:IMCC) & MacroGenics (NASDAQ:MGNX) Head to Head Survey - Defense World
Macrogenics (MGNX) Stock Analysis Report | Financials & Insights - Benzinga
MGNX (Macrogenics) EPS without NRI : $-1.20 (TTM As of Sep. 2025) - GuruFocus
MGNX (Macrogenics) Operating Cash Flow per Share : $-2.58 (TTM As of Sep. 2025) - GuruFocus
MacroGenics, Inc. (NASDAQ:MGNX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
MacroGenics, Inc. (NASDAQ:MGNX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference - Enidnews.com
Taking the lead: Macrogenics Inc (MGNX) - Setenews
MacroGenics (Nasdaq: MGNX) to Present at 8th Evercore Healthcare Conference Fireside Chat - Stock Titan
Is MacroGenics Inc. stock cheap at current valuationEarnings Recap Summary & High Conviction Buy Zone Picks - newser.com
Macrogenics Inc Stock (MGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):